
Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target
Ultragenyx Pharmaceutical (RARE) Analyst Ratings
Bulls say
Ultragenyx Pharmaceutical is viewed positively because its core commercial base is proving resilient, with 3Q26 Dojolvi revenue of $30M versus $28M consensus and Evkeeza revenue of $24M versus $20M consensus, reinforcing that multiple franchises can still outperform expectations despite recent pipeline setbacks. Management also reiterated FY26 guidance and profitability in FY27 while outlining a 20% workforce reduction and capping FY27 R&D below $350M and SG&A below $375M, a sharper expense discipline that should materially improve operating leverage. Beyond cost cuts, the company has a deep rare-disease pipeline and a valuable commercial platform led by Crysvita, while the approval-related PRV windfall could generate about $400M in non-dilutive capital to support growth and de-risk execution.
Bears say
Ultragenyx Pharmaceutical is facing a weakened fundamental profile after the ASPIRE phase 3 failure for GTX-102 removed a major long-term growth driver and raised doubts about the company’s ability to convert pipeline assets into durable revenue. Analysts also trimmed FY26 Crysvita revenue to $502M, cut Dojolvi and Mepsevii trajectories, and reduced FY26 revenue by about $14M while noting the loss of UX701 and uncertainty around setrusumab leaves few clear pipeline bright spots. With management shifting toward expense reductions, focusing on existing products, and still targeting profitability around FY27, the stock may remain range bound as investors question whether the commercial portfolio can offset shrinking pipeline value.
This aggregate rating is based on analysts' research of Ultragenyx Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Ultragenyx Pharmaceutical (RARE) Analyst Forecast & Price Prediction
Start investing in Ultragenyx Pharmaceutical (RARE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ultragenyx Pharmaceutical (RARE) Forecast
Ultragenyx Pharmaceutical (RARE) Analyst Forecast & Price Prediction
Start investing in Ultragenyx Pharmaceutical (RARE)
Order type
Buy in
Order amount
Est. shares
0 shares